Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cosmetic formulation, developed by the Poznan University of Medical Sciences, is a topical cream designed to treat skin aging. The product utilizes a base composed of Creagel EZ 7 and Alphaflow 20 (emulsifying and emollient agents) loaded with autologous platelet-rich fibrin (PRF) at a concentration of 2 mL per 100 g of cream. PRF is a second-generation platelet concentrate derived from the patient's own blood, containing a high concentration of platelets, growth factors (such as PDGF, TGF-β, and VEGF), and a fibrin matrix. When applied topically, these components promote tissue regeneration, enhance skin hydration, and improve elasticity by stimulating cellular processes in the dermis and epidermis. Clinical evaluation in healthy volunteers has demonstrated its efficacy in reducing transepidermal water loss (TEWL) and improving overall skin barrier function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Creagel EZ 7 + Alphaflow 20 + autologous platelet-rich fibrin.